Showing results (1271-1280 of 1,373) with videos related to

Sort By:
Pageof 138
Future Oncology (London, England)|May 22, 2023
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myelomaThierry Facon, Shaji K Kumar, Torben Plesner, et al.
Frontiers in Robotics and AI|June 28, 2021
Model-Augmented Haptic Telemanipulation: Concept, Retrospective Overview, and Current Use CasesThomas Hulin, Michael Panzirsch, Harsimran Singh, et al.
Stroke|September 5, 2019
Confirmatory Study of Time-Dependent Computed Tomographic Perfusion Thresholds for Use in Acute Ischemic StrokeWu Qiu, Hulin Kuang, Ting Y Lee, et al.
Cancer Medicine|March 15, 2025
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020Laure Vincent, Olivier Decaux, Aurore Perrot, et al.
BMC Medicine|May 30, 2024
Comparison of children and adults in deep brain stimulation for Tourette Syndrome: a large-scale multicenter study of 102 cases with long-term follow-upYuan Gao, Shu Wang, Anni Wang, et al.
Cell Stem Cell|May 18, 2021
Integrated pseudotime analysis of human pre-implantation embryo single-cell transcriptomes reveals the dynamics of lineage specificationDimitri Meistermann, Alexandre Bruneau, Sophie Loubersac, et al.
British Journal of Haematology|January 21, 2017
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trialJin Lu, Jae H Lee, Shang-Yi Huang, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2024
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY CohortT Chalopin, M Macro, O Decaux, et al.
Physical Review Letters|February 2, 2013
Relativistic high-current electron-beam stopping-power characterization in solids and plasmas: collisional versus resistive effectsB Vauzour, J J Santos, A Debayle, et al.
Immunotherapy|November 24, 2020
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparisonPhilippe Moreau, Benjamin Hebraud, Thierry Facon, et al.
Pageof 138